Dr. Emily Mcgowan, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,059 | 7 | 87.1% |
| Unspecified | $1,269 | 4 | 6.9% |
| Travel and Lodging | $728.14 | 2 | 3.9% |
| Food and Beverage | $389.72 | 7 | 2.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $5,208 | 8 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $4,140 | 1 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,870 | 4 | $0 (2024) |
| Shire North American Group Inc | $3,300 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $1,074 | 1 | $0 (2024) |
| Celgene Corporation | $853.14 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,937 | 11 | E.R. Squibb & Sons, L.L.C. ($4,140) |
| 2023 | $3,855 | 2 | Regeneron Pharmaceuticals, Inc. ($3,855) |
| 2022 | $81.07 | 1 | Regeneron Pharmaceuticals, Inc. ($81.07) |
| 2019 | $1,273 | 5 | Regeneron Pharmaceuticals, Inc. ($1,273) |
| 2018 | $3,300 | 1 | Shire North American Group Inc ($3,300) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,140.00 | General |
| 09/20/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $506.25 | General |
| 09/20/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $65.01 | General |
| 09/20/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/20/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $29.99 | General |
| 09/19/2024 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $221.89 | General |
| 04/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Consulting Fee | Cash or cash equivalent | $1,845.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Consulting Fee | Cash or cash equivalent | $1,845.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,965.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/11/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $889.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/24/2022 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $81.07 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/04/2019 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $828.92 | Research |
| Study: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/04/2019 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $206.30 | Research |
| Study: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/04/2019 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $130.00 | Research |
| Study: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/03/2019 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $103.75 | Research |
| Study: A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/23/2019 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $3.65 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2018 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis EoE | Regeneron Pharmaceuticals, Inc. | $1,269 | 4 |
About Dr. Emily Mcgowan, M.D
Dr. Emily Mcgowan, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1053584532.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emily Mcgowan, M.D has received a total of $18,445 in payments from pharmaceutical and medical device companies, with $9,937 received in 2024. These payments were reported across 20 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($16,059).
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Allergy & Immunology
- Location Charlottesville, VA
- Active Since 04/07/2008
- Last Updated 08/10/2023
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1053584532
Products in Payments
- DUPIXENT (Biological) $5,208
- EOHILIA (Drug) $3,870
- TEZSPIRE (Biological) $1,074
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Charlottesville
Hillary Maitland, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $389,378
Brian Wentworth
Student in an Organized Health Care Education/Training Program — Payments: $227,368
Charles Su
Student in an Organized Health Care Education/Training Program — Payments: $41,413
Michael Mccabe, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $23,740
Laahn Foster, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $18,613
Xudong Li, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $17,265